Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs Mevo Health

Elara MD
Graded #467

Lower grade

vs+6.700000000000003
Mevo Health
Graded #327

Higher grade

The verdict

Mevo Health takes it — 60.2/100 to 53.5/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +16
40
56
Dose & formulationMevo Health +29
54
83
Clinical oversightMevo Health +4
63
67
Labs & monitoringEven
52
52
FulfillmentElara MD +9
66
57
Contract termsElara MD +35
55
20
Elara MD · left barMevo Health · right bar

The numbers

MetricElara MDMevo Health
WeighScore53.5/10060.2/100
GradeCC
Scorecard rank#467#327
Semaglutide$249/mo (0.2 mg dose, compounded)$199/mo (all doses, compounded)
Tirzepatide$349/mo (2.0 mg dose, compounded)$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Elara MD

Graded #467 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard